Covaxin Efficacy
- All
- News
- Videos
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
No Doubts On Safety, Efficacy: WHO Chief Scientist On Covaxin Suspension
Soumya Swaminathan, Chief Scientist at the World Health Organisation, today assured that the freeze on Bharat Biotech's Covaxin supply does not involve the safety or efficacy of the vaccine, but some issues in manufacturing processes for which correc
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Covaxin 77.8% Effective Against Covid, Says Lancet Study
Covaxin, the coronavirus vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet.
-
Covaxin Found To Be 77.8% Effective Against Covid In Lancet Study
Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.
-
Approval To Covaxin Expands Availability Of Vaccines, Says WHO Official
The Emergency Use Listing nod to Bharat Biotech's Covaxin, which was found to have 78 per cent efficacy against COVID-19 of any severity, expands the availability of vaccines, the most effective medical tools to end the pandemic, a WHO official said
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Covaxin Works Against UK Strain, Variant Found in India: Bharat Biotech
Bharat Biotech has said its vaccine Covaxin is effective against the aggressively virulent B.1.167 strain of Covid detected in India and the UK variant of the virus B.1.1.7.
-
Covaxin Booster Enhances Efficacy Against Delta, Omicron Variants: Study
The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19's Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found.
-
No Doubts On Safety, Efficacy: WHO Chief Scientist On Covaxin Suspension
Soumya Swaminathan, Chief Scientist at the World Health Organisation, today assured that the freeze on Bharat Biotech's Covaxin supply does not involve the safety or efficacy of the vaccine, but some issues in manufacturing processes for which correc
-
WHO Suspends UN Supply Of Covaxin; No Impact On Efficacy, Says Bharat Biotech
The World Health Organisation said on Saturday it has suspended supply through United Nations agencies of COVID-19 vaccine Covaxin, produced by India's Bharat Biotech, to allow the manufacturer to upgrade facilities.
-
Covishield, Covaxin To Be Available In Hospitals, Clinics In New Approval
Covishield and Covaxin have been cleared by India's drugs regulator for sale in the market, sources have said.
-
Covaxin Meets WHO Criteria For Delta, Shows Lancet Study: Bharat Biotech
Hyderabad-based Bharat Biotech has said that the results compare well with 65.2 per cent efficacy against Delta variant obtained during controlled phase 3 clinical trials of COVAXIN conducted among the general population.
-
Covaxin 77.8% Effective Against Covid, Says Lancet Study
Covaxin, the coronavirus vaccine developed by the government's medical research agency and Bharat Biotech, was found to have a 77.8 per cent efficacy rate against symptomatic COVID-19 in a long-awaited analysis published in The Lancet.
-
Covaxin Found To Be 77.8% Effective Against Covid In Lancet Study
Covaxin, a vaccine developed by government's medical research agency and Bharat Biotech International Ltd., was found to have a 77.8% efficacy rate against symptomatic Covid-19 in a long-awaited analysis published in The Lancet.
-
Approval To Covaxin Expands Availability Of Vaccines, Says WHO Official
The Emergency Use Listing nod to Bharat Biotech's Covaxin, which was found to have 78 per cent efficacy against COVID-19 of any severity, expands the availability of vaccines, the most effective medical tools to end the pandemic, a WHO official said
-
Covaxin 77.8% Effective In Phase 3 Trial Data: Sources
Coronavirus: Bharat Biotech's Covaxin is 77.8 per cent effective in protecting against COVID-19 - according to results of Phase III trial data approved by the DCGI's Subject Expert Committee - sources said on Tuesday afternoon.
-
Covaxin Works Against UK Strain, Variant Found in India: Bharat Biotech
Bharat Biotech has said its vaccine Covaxin is effective against the aggressively virulent B.1.167 strain of Covid detected in India and the UK variant of the virus B.1.1.7.
